Tenaya Therapeutics reports Q4 EPS (61c), consensus (65c)

As of December 31, 2022, cash, cash equivalents and investments in marketable securities were $204.2M. Tenaya expects current cash, cash equivalents and investments in marketable securities will be sufficient to fund the company into the first half of 2025. "Tenaya enters 2023 well capitalized and with meaningful milestones ahead," said Faraz Ali, Chief Executive Officer of Tenaya. "This year, we look forward to beginning clinical testing of our lead gene therapy candidate, TN-201, sharing data from our first-in-human clinical trial of TN-301, and submitting an IND for our TN-401 gene therapy candidate, as well as presenting additional data detailing insights on current pipeline candidates and emerging platform innovations."